{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:11:04Z","timestamp":1779376264561,"version":"3.53.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Opinion statement<\/jats:title>\n          <jats:p>Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments.\u00a0Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases.\u00a0Use of immunotherapy (checkpoint inhibitors) and targeted therapy (BRAF\/MEK inhibitors) significantly changed the outcome in patients with melanoma metastases. Currently, ipilimumab and nivolumab (COMBO) is the preferred first-line systemic therapy for all patients with asymptomatic brain metastases, regardless of BRAF status (BRAF wild-type and BRAF-mutated). Although at the moment there is no consensus on the concomitant use of SRS and COMBO, results from clinical trials suggest that this combined treatment modality should be considered the standard of care for melanoma patients with brain metastases. However, further clinical research is required to define optimal treatment modalities for routine management of melanoma brain lesions.<\/jats:p>","DOI":"10.1007\/s11864-024-01289-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:33:00Z","timestamp":1735889580000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview"],"prefix":"10.1007","volume":"26","author":[{"given":"Marko","family":"Lens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"5","key":"1289_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1289_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3978\/j.issn.2304-3865.2015.06.04","volume":"4","author":"MR Neagu","year":"2015","unstructured":"Neagu MR, Gill CM, Batchelor TT, Brastianos PK. Genomic profiling of brain metastases: current knowledge and new frontiers. Chin Clin Oncol. 2015;4(2):22. https:\/\/doi.org\/10.3978\/j.issn.2304-3865.2015.06.04.","journal-title":"Chin Clin Oncol"},{"issue":"8","key":"1289_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687\u201396. https:\/\/doi.org\/10.1002\/cncr.25634.","journal-title":"Cancer"},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pcmr.12538","volume":"29","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016;29:627\u201342.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"1289_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15075","volume":"33","author":"A Knox","year":"2024","unstructured":"Knox A, Wang T, Shackleton M, Ameratunga M. Symptomatic brain metastases in melanoma. Exp Dermatol. 2024;33(4): e15075. https:\/\/doi.org\/10.1111\/exd.15075.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1289_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","volume":"1","author":"S Goyal","year":"2015","unstructured":"Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL. Clinical management of multiple melanoma brain metastases: a systematic review. JAMA Oncol. 2015;1(5):668\u201376. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1206.","journal-title":"JAMA Oncol"},{"key":"1289_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fonc.2012.00073","volume":"2","author":"D Greene-Schloesser","year":"2012","unstructured":"Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: a review. Front Oncol. 2012;2:73. https:\/\/doi.org\/10.3389\/fonc.2012.00073.","journal-title":"Front Oncol"},{"key":"1289_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ctro.2022.09.005","volume":"37","author":"T Nakano","year":"2022","unstructured":"Nakano T, Aoyama H, Onodera S, Igaki H, Matsumoto Y, Kanemoto A, et al. Reduced-dose WBRT combined with SRS for 1\u20134 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control. Clin Transl Radiat Oncol. 2022;37:116\u201329. https:\/\/doi.org\/10.1016\/j.ctro.2022.09.005.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"1289_CR9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ijrobp.2010.01.039","volume":"78","author":"V Gondi","year":"2010","unstructured":"Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole brain radiotherapy: a \u201chow-to\u201d technique, utilizing helical tomotherapy and LINAC-based intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):1244\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.039.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1289_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.radonc.2010.09.013","volume":"97","author":"V Gondi","year":"2010","unstructured":"Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010;97:370\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2010.09.013.","journal-title":"Radiother Oncol"},{"key":"1289_CR11","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","volume":"21","author":"MP Mehta","year":"2003","unstructured":"Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529\u201336. https:\/\/doi.org\/10.1200\/JCO.2003.12.122.","journal-title":"J Clin Oncol"},{"issue":"34","key":"1289_CR12","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","volume":"32","author":"V Gondi","year":"2014","unstructured":"Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.57.2909.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1289_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.adro.2019.07.006","volume":"4","author":"JA Bovi","year":"2019","unstructured":"Bovi JA, Pugh SL, Sabsevitz D, Robinson CG, Paulson E, Mehta MP, et al. Pretreatment volume of MRI-determined white matter injury predicts neurocognitive decline after hippocampal avoidant whole-brain radiation therapy for brain metastases: secondary analysis of NRG oncology radiation therapy oncology group 0933. Adv Radiat Oncol. 2019;4(4):579\u201386. https:\/\/doi.org\/10.1016\/j.adro.2019.07.006.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"1289_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2023.04.030","volume":"117","author":"V Gondi","year":"2023","unstructured":"Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, et al. Sustained preservation of cognition and prevention of patient-reported symptoms with hippocampal avoidance during whole-brain radiation therapy for brain metastases: final results of NRG oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117(3):571\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.030.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1289_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol. 2020;38:1019\u201329.","journal-title":"J Clin Oncol"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"1342669","DOI":"10.3389\/fonc.2024.1342669","volume":"14","author":"R Liu","year":"2024","unstructured":"Liu R, Gong G, Meng K, Du S, Yin Y. Hippocampal sparing in whole-brain radiotherapy for brain metastases: controversy, technology and the future. Front Oncol. 2024;14:1342669. https:\/\/doi.org\/10.3389\/fonc.2024.1342669.","journal-title":"Front Oncol"},{"issue":"1","key":"1289_CR17","doi-asserted-by":"publisher","first-page":"CD003869","DOI":"10.1002\/14651858.CD003869.pub4","volume":"1","author":"MN Tsao","year":"2018","unstructured":"Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2018;1(1):CD003869. https:\/\/doi.org\/10.1002\/14651858.CD003869.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"33","key":"1289_CR18","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.19.01414","volume":"37","author":"AM Hong","year":"2019","unstructured":"Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, et al. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial. J Clin Oncol. 2019;37(33):3132\u201341. https:\/\/doi.org\/10.1200\/JCO.19.01414.","journal-title":"J Clin Oncol"},{"key":"1289_CR19","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.2147\/CMAR.S204729","volume":"11","author":"H Hauswald","year":"2019","unstructured":"Hauswald H, Bernhardt D, Krug D, Katayama S, Habl G, Lorenzo Bermejo J, et al. Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma \u2013 final results of the BRAIN-RT trial. Cancer Manag Res. 2019;11:4669\u201376. https:\/\/doi.org\/10.2147\/CMAR.S204729.","journal-title":"Cancer Manag Res"},{"key":"1289_CR20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/neuonc\/noaa092","volume":"22","author":"KD Westover","year":"2020","unstructured":"Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuvet S, et al. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol. 2020;22:1831\u20139. https:\/\/doi.org\/10.1093\/neuonc\/noaa092.","journal-title":"Neuro Oncol"},{"issue":"11","key":"1289_CR21","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cncr.32787","volume":"126","author":"I Popp","year":"2020","unstructured":"Popp I, Rau S, Hintz M, Schneider J, Bilger A, Fennell JT, et al. Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer. 2020;126(11):2694\u2013703. https:\/\/doi.org\/10.1002\/cncr.32787.","journal-title":"Cancer"},{"key":"1289_CR22","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1186\/s12885-023-11739-9","volume":"23","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang T, Guo Z, Zhao F, Li J, Li Y, et al. Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases. BMC Cancer. 2023;23:1240. https:\/\/doi.org\/10.1186\/s12885-023-11739-9.","journal-title":"BMC Cancer"},{"issue":"1","key":"1289_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12253-018-0383-y","volume":"26","author":"A Dobi","year":"2020","unstructured":"Dobi A, Fodor E, Maraz A, Egy\u00fcd Z, Cserh\u00e1ti A, Tiszlavicz L, et al. Boost irradiation integrated to whole brain radiotherapy in the management of brain metastases. Pathol Oncol Res. 2020;26(1):149\u201357. https:\/\/doi.org\/10.1007\/s12253-018-0383-y.","journal-title":"Pathol Oncol Res"},{"key":"1289_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12885-020-07011-z","volume":"20","author":"AL Grosu","year":"2020","unstructured":"Grosu AL, Frings L, Bentsalo I, Oehlke O, Brenner F, Bilger A, et al. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD)\u2014a phase II prospective randomized multicenter trial (NOA-14, ARO 2015\u20133, DKTK-ROG). BMC Cancer. 2020;20:532.","journal-title":"BMC Cancer"},{"key":"1289_CR25","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/s0360-3016(01)02772-9","volume":"52","author":"C Yu","year":"2002","unstructured":"Yu C, Chen JC, Apuzzo ML, O\u2019Day S, Giannotta SL, Weber JS, Petrovich Z. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52:1277\u201387. https:\/\/doi.org\/10.1016\/s0360-3016(01)02772-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1289_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1227\/01.NEU.0000255342.10780.52","volume":"60","author":"D Mathieu","year":"2007","unstructured":"Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007;60(3):471\u201381. https:\/\/doi.org\/10.1227\/01.NEU.0000255342.10780.52.","journal-title":"Neurosurgery"},{"issue":"3","key":"1289_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","volume":"114","author":"DN Liew","year":"2011","unstructured":"Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of Gamma knife surgery for melanoma brain metastases. Clinical article J Neurosurg. 2011;114(3):769\u201379. https:\/\/doi.org\/10.3171\/2010.5.JNS1014.","journal-title":"Clinical article J Neurosurg"},{"issue":"6","key":"1289_CR28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.wneu.2013.02.025","volume":"82","author":"MT Neal","year":"2014","unstructured":"Neal MT, Chan MD, Lucas JT Jr, Loganathan A, Dillingham C, Pan E, et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2014;82(6):1250\u20135. https:\/\/doi.org\/10.1016\/j.wneu.2013.02.025.","journal-title":"World Neurosurg"},{"issue":"3","key":"1289_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000489948","volume":"96","author":"S Matsunaga","year":"2018","unstructured":"Matsunaga S, Shuto T, Yamamoto M, Yomo S, Kondoh T, Kobayashi T, et al. Gamma knife radiosurgery for metastatic brain tumors from malignant melanomas: a Japanese multi-institutional cooperative and retrospective cohort study (JLGK1501). Stereotact Funct Neurosurg. 2018;96(3):162\u201371. https:\/\/doi.org\/10.1159\/000489948.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"3","key":"1289_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2478\/raon-2022-0032","volume":"56","author":"JF Thompson","year":"2022","unstructured":"Thompson JF, Williams GJ, Hong AM. Radiation therapy for melanoma brain metastases: a systematic review. Radiol Oncol. 2022;56(3):267\u201384. https:\/\/doi.org\/10.2478\/raon-2022-0032.","journal-title":"Radiol Oncol"},{"issue":"10","key":"1289_CR31","first-page":"619","volume":"20","author":"FY Kreidieh","year":"2022","unstructured":"Kreidieh FY, Tawbi HA. Current and emerging options for patients with melanoma brain metastases. Clin Adv Hematol Oncol. 2022;20(10):619\u201327.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"1289_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1227\/neu.0000000000002482","volume":"93","author":"Z Wei","year":"2023","unstructured":"Wei Z, Luy DD, Jose S, Deng H, Yavan S, Worrell S, et al. Single-session Gamma knife radiosurgery for patients with 20 or more brain metastases. Neurosurgery. 2023;93(4):857\u201366. https:\/\/doi.org\/10.1227\/neu.0000000000002482.","journal-title":"Neurosurgery"},{"issue":"5","key":"1289_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3171\/2020.3.JNS193369","volume":"134","author":"GN Bowden","year":"2020","unstructured":"Bowden GN, Kim JO, Faramand A, Fallon K, Flickinger J, Lunsford LD. Clinical dose profile of Gamma knife stereotactic radiosurgery for extensive brain metastases. J Neurosurg. 2020;134(5):1430\u20134. https:\/\/doi.org\/10.3171\/2020.3.JNS193369.","journal-title":"J Neurosurg"},{"issue":"2","key":"1289_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.adro.2019.10.003","volume":"5","author":"MD Riina","year":"2019","unstructured":"Riina MD, Stambaugh CK, Huber KE. Hippocampal dosimetry and the necessity of hippocampal-sparing in gamma knife stereotactic radiosurgery for extensive brain metastases. Adv Radiat Oncol. 2019;5(2):180\u20138. https:\/\/doi.org\/10.1016\/j.adro.2019.10.003.","journal-title":"Adv Radiat Oncol"},{"issue":"11","key":"1289_CR35","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1002\/cam4.3021","volume":"9","author":"B Gatterbauer","year":"2020","unstructured":"Gatterbauer B, Hirschmann D, Eberherr N, Untersteiner H, Cho A, Shaltout A, et al. Toxicity and efficacy of Gamma knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study. Cancer Med. 2020;9(11):4026\u201336. https:\/\/doi.org\/10.1002\/cam4.3021.","journal-title":"Cancer Med"},{"issue":"1","key":"1289_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10555-020-09949-9","volume":"40","author":"PY Borius","year":"2021","unstructured":"Borius PY, R\u00e9gis J, Carpentier A, Kalamarides M, Valery CA, Latorzeff I. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and\/or immunotherapy) in brain metastases: a systematic review. Cancer Metastasis Rev. 2021;40(1):341\u201354. https:\/\/doi.org\/10.1007\/s10555-020-09949-9.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1289_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1754-9485.13403","volume":"66","author":"MD Shanker","year":"2022","unstructured":"Shanker MD, Garimall S, Gatt N, Foley H, Crowley S, Le Cornu E, et al. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. J Med Imaging Radiat Oncol. 2022;66(4):536\u201345. https:\/\/doi.org\/10.1111\/1754-9485.13403.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"10","key":"1289_CR38","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms19103054","volume":"19","author":"EJ Lehrer","year":"2018","unstructured":"Lehrer EJ, McGee HM, Peterson JL, Vallow L, Ruiz-Garcia H, Zaorsky NG, et al. Stereotactic radiosurgery and immune checkpoint inhibitors in the management of brain metastases. Int J Mol Sci. 2018;19(10):3054. https:\/\/doi.org\/10.3390\/ijms19103054.","journal-title":"Int J Mol Sci"},{"key":"1289_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","volume":"53","author":"SG Kroeze","year":"2017","unstructured":"Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. 2017;53:25\u201337. https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.013.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"1289_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6147","volume":"11","author":"BD Weaver","year":"2019","unstructured":"Weaver BD, Goodman JR, Jensen R. Concurrent radiosurgery and systemic therapies for melanoma brain metastases: a systematic review. Cureus. 2019;11(11): e6147. https:\/\/doi.org\/10.7759\/cureus.6147.","journal-title":"Cureus"},{"key":"1289_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quinones-Hinojosa A, Zaorsky NG, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104\u201312. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.025.","journal-title":"Radiother Oncol"},{"key":"1289_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102830","volume":"144","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, De Stefani A, Trevisan F, Parati C, Inno A, Merelli B, et al. Combination of radiotherapy and immunotherapy for brain metastases: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;144: 102830. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102830.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1289_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-018-03020-y","volume":"141","author":"VM Lu","year":"2019","unstructured":"Lu VM, Goyal A, Rovin RA, Lee A, McDonald KL. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol. 2019;141(1):1\u201312. https:\/\/doi.org\/10.1007\/s11060-018-03020-y.","journal-title":"J Neurooncol"},{"issue":"6","key":"1289_CR44","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/ijc.32696","volume":"146","author":"MP van Opijnen","year":"2020","unstructured":"van Opijnen MP, Dirven L, Coremans IEM, Taphoorn MJB, Kapiteijn EHW. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: a systematic review. Int J Cancer. 2020;146(6):1479\u201389. https:\/\/doi.org\/10.1002\/ijc.32696.","journal-title":"Int J Cancer"},{"key":"1289_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102923","volume":"149","author":"Y Pin","year":"2020","unstructured":"Pin Y, Paix A, Todeschi J, Antoni D, Proust F, Noel G. Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: a systematic review. Crit Rev Oncol Hematol. 2020;149: 102923. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102923.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1289_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104462","volume":"202","author":"GJ Williams","year":"2024","unstructured":"Williams GJ, Hong AM, Thompson JF. Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis. Crit Rev Oncol Hematol. 2024;202: 104462. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104462.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1289_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102083","volume":"89","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, et al. Melanoma brain metastases - interdisciplinary management recommendations 2020. Cancer Treat Rev. 2020;89: 102083. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102083.","journal-title":"Cancer Treat Rev"},{"key":"1289_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885472","volume":"12","author":"XL Tan","year":"2022","unstructured":"Tan XL, Le A, Lam FC, Scherrer E, Kerr RG, Lau AC, et al. Current treatment approaches and global consensus guidelines for brain metastases in melanoma. Front Oncol. 2022;12: 885472. https:\/\/doi.org\/10.3389\/fonc.2022.885472.","journal-title":"Front Oncol"},{"key":"1289_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","volume":"126","author":"C Garbe","year":"2020","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer. 2020;126:159\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.015.","journal-title":"Eur J Cancer"},{"key":"1289_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2022. Eur J Cancer. 2022;170:256\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1289_CR51","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO guidelines committee. Ann Oncol. 2020;31(11):1435\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.004.","journal-title":"Ann Oncol"},{"issue":"11","key":"1289_CR52","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.016.","journal-title":"Ann Oncol"},{"key":"1289_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2020.10.013","volume":"142","author":"AM Hong","year":"2021","unstructured":"Hong AM, Waldstein C, Shivalingam B, Carlino MS, Atkinson V, Kefford RF, et al. Management of melanoma brain metastases: evidence-based clinical practice guidelines by Cancer Council Australia. Eur J Cancer. 2021;142:10\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.013.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1289_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, et al. NCCN guidelines insights: central nervous system cancers, version 2.2022. J Natl Compr Canc Netw. 2023;21(1):12\u201320. https:\/\/doi.org\/10.6004\/jnccn.2023.0002.","journal-title":"J Natl Compr Canc Netw"},{"key":"1289_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40:492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314.","journal-title":"J Clin Oncol"},{"key":"1289_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113542","volume":"199","author":"M Mandal\u00e0","year":"2024","unstructured":"Mandal\u00e0 M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, et al. Combined immunotherapy in melanoma patients with brain metastases: a multicenter international study. Eur J Cancer. 2024;199: 113542. https:\/\/doi.org\/10.1016\/j.ejca.2024.113542.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1289_CR57","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1080\/02688697.2021.2022098","volume":"37","author":"S Badrigilan","year":"2023","unstructured":"Badrigilan S, Meola A, Chang SD, Rezaeian S, Nemati H, Almasi T, Rostampour N. Stereotactic radiosurgery with immune checkpoint inhibotors for brainmetastases: a meta-analysis study. Br J Neurosurg. 2023;37(6):1533\u201343. https:\/\/doi.org\/10.1080\/02688697.2021.2022098.","journal-title":"Br J Neurosurg"},{"key":"1289_CR58","doi-asserted-by":"publisher","first-page":"1025664","DOI":"10.3389\/fonc.2022.1025664","volume":"12","author":"XL Tan","year":"2022","unstructured":"Tan XL, Le A, Scherrer E, Tang H, Kiehl N, Han J, et al. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Front Oncol. 2022;12:1025664. https:\/\/doi.org\/10.3389\/fonc.2022.1025664.","journal-title":"Front Oncol"},{"key":"1289_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","volume":"151","author":"CM Sha","year":"2020","unstructured":"Sha CM, Lehrer EJ, Hwang C, Trifiletti DM, Mackley HB, Drabick JJ, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2020;151:141\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.035.","journal-title":"Radiother Oncol"},{"key":"1289_CR60","doi-asserted-by":"publisher","unstructured":"Franklin C, Mohr P, Bluhm L, GrimmelmannI, Gutzmer R, Meier F, et al. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. J Immunother Cancer 2022;10(6):e004509. https:\/\/doi.org\/10.1136\/jitc-2022-004509.","DOI":"10.1136\/jitc-2022-004509"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-024-01289-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:40:50Z","timestamp":1737985250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-024-01289-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s11864-024-01289-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"13 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}